TERAPIA GENICA ANTI-FACTOR DE CRECIMIENTO TRANSFORMANTE BETA

• Main Author: BORDER, WAYNE, A
• Format: Patent
• Language: Spanish
• Published: 01.02.2003
• Edition: 7
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

LA PRESENTE INVENCION PROPORCIONA METODOS PARA REDUCIR UNA PATOLOGIA EN UN SUJETO QUE SE CARACTERIZA POR UNA ACUMULACION DELETEREA DE MATRIZ EXTRACELULAR INDUCIDA POR TGF-{BE} EN UN TEJIDO INTRODUCIENDO UN ACIDO NUCLEICO QUE CODIFICA UN AGENTE INHIBIDOR ESPECIFICO DE TGF-{BE} O UN FRAGMENTO ACTIVO DEL MISMO EN UNA CELULA DEL SUJETO. EN UNA REALIZACION, EL ACIDO NUCLEICO QUE CODIFICA EL AGENTE INHIBIDOR ESPECIFICO DE TGF-{BE} SE INTRODUCE EN UNA CELULA IN VIVO MEDIANTE INYECCION, POR EJEMPLO, EN EL MUSCULO ESQUELETICO. EN OTRA REALIZACION, EL ACIDO NUCLEICO QUE CODIFICA EL AGENTE INHIBIDOR ESPECIFICO DE TGF-{BE} SE TRANSFECTA EN UNA CELULA EX VIVO PARA OBTENER UNA CELULA QUE EXPRESA EL AGENTE Y, A CONTINUACION, SE ADMINISTRA LA CELULA AL SUJETO A TRATAR. LOS AGENTES INHIBIDORES ESPECIFICOS DE TGF-{BE} DE LA PRESENTE INVENCION INCLUYEN, ENTRE OTROS, MIEMBROS DE LA FAMILIA DECORINA DE LOS PROTEOGLICANOS TALES COMO DECORINA, BIGLICANO, FIBROMODULINA Y LUMICANO O UN ANTICUERPO ESPECIFICO PARA TGF-{BE}. LAS PATOLOGIAS QUE PUEDEN RESULTAR REDUCIDAS MEDIANTE LA PRESENTE INVENCION INCLUYEN DIVERSAS ENFERMEDADES Y ESTADOS FIBROTICOS. The present invention provides methods for reducing a pathology in a subject characterized by a deleterious accumulation of TGF- beta -induced extracellular matrix in a tissue by introducing a nucleic acid encoding a TGF beta -specific inhibitory agent or active fragment thereof into a cell in the subject. In one embodiment, the nucleic acid encoding the TGF- beta specific inhibitory agent is introduced into a cell in vivo by injection, for example, in skeletal muscle. In another embodiment, the nucleic acid encoding the TGF- beta specific inhibitory agent is transfected into a cell ex vivo to obtain a cell expressing the agent, and the cell is then administered into the subject to be treated. TGF- beta specific inhibitory agents of the present invention include, but are not limited to, members of the decoring family of proteoglycans such as decorin, biglycan, fibromodulin and lumican or an antibody specific for TGF- beta . Pathologies that can be reduced by the present invention include various fibrotic diseases and conditions.